ZURICH, June 29 (Reuters) - The U.S. Food and Drug Administration has agreed to review Swiss generics drugmaker Sandoz's (SDZ.S), opens new tab two generic tirzepatide GLP-1s that, if approved, would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results